Tumor Budding Cells, Cancer Stem Cells and Epithelial-mesenchymal Transition-type Cells in Pancreatic Cancer

Overview

Journal Front Oncol

Specialty Oncology

Date 2013 Jan 15

PMID 23316479

Citations 41

Authors

Eva Karamitopoulou

Affiliations

Soon will be listed here.

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal cancers with a 5-year survival rate of less than 5%. Moreover, PDAC escapes early detection and resists treatment. Multiple combinations of genetic alterations are known to occur in PDAC including mutational activation of KRAS, inactivation of p16/CDKN2A and SMAD4 (DPC4) and dysregulation of PTEN/PI3K/AKT signaling. Through their interaction with Wingless-INT pathway, the downstream molecules of these pathways have been implicated in the promotion of epithelial-mesenchymal transition (EMT). Emerging evidence has demonstrated that cancer stem cells (CSCs), small populations of which have been identified in PDAC, and EMT-type cells play critical roles in drug resistance, invasion, and metastasis in pancreatic cancer. EMT may be histologically represented by the presence of tumor budding which is described as the occurrence of single tumor cells or small clusters (<5) of dedifferentiated cells at the invasive front of gastrointestinal (including colorectal, oesophageal, gastric, and ampullary) carcinomas and is linked to poor prognosis. Tumor budding has recently been shown to occur frequently in PDAC and to be associated with adverse clinicopathological features and decreased disease-free and overall survival. The aim of this review is to present a short overview on the morphological and molecular aspects that underline the relationship between tumor budding cells, CSCs, and EMT-type cells in PDAC.

Citing Articles

Gene Mutation Associated with Grade of Tumor Budding and Peripheral Immunoinflammatory Indices in Patients with Colorectal Cancer.

Liang L, Guo X, Ye W, Liu Y Int J Gen Med. 2024; 17:4769-4780.

PMID: 39440104 PMC: 11495189. DOI: 10.2147/IJGM.S487525.

The radiomorphological appearance of the invasive margin in pancreatic cancer is associated with tumor budding.

Mayer P, Hausen A, Steinle V, Bergmann F, Kauczor H, Loos M Langenbecks Arch Surg. 2024; 409(1):167.

PMID: 38809279 PMC: 11136832. DOI: 10.1007/s00423-024-03355-3.

MicroRNAs as the critical regulators of epithelial mesenchymal transition in pancreatic tumor cells.

Tolue Ghasaban F, Ghanei M, Mahmoudian R, Taghehchian N, Abbaszadegan M, Moghbeli M Heliyon. 2024; 10(9):e30599.

PMID: 38726188 PMC: 11079401. DOI: 10.1016/j.heliyon.2024.e30599.

Epithelial and Mesenchymal-like Pancreatic Cancer Cells Exhibit Different Stem Cell Phenotypes Associated with Different Metastatic Propensities.

Philipp L, Yesilyurt U, Surrow A, Kunstner A, Mehdorn A, Hauser C Cancers (Basel). 2024; 16(4).

PMID: 38398077 PMC: 10886860. DOI: 10.3390/cancers16040686.

Glial cell-derived soluble factors increase the metastatic potential of pancreatic adenocarcinoma cells and induce epithelial-to-mesenchymal transition.

Garcia-Reyes B, Kuzmanov I, Schneider R, Schneiker B, Efferz P, Kalff J J Cancer Res Clin Oncol. 2023; 149(15):14315-14327.

PMID: 37572121 PMC: 10590291. DOI: 10.1007/s00432-023-05133-y.

References

Kirchner T, Brabletz T . Patterning and nuclear beta-catenin expression in the colonic adenoma-carcinoma sequence. Analogies with embryonic gastrulation. Am J Pathol. 2000; 157(4):1113-21. PMC: 1850184. DOI: 10.1016/s0002-9440(10)64626-3. View

Wu Y, Zhou B . Inflammation: a driving force speeds cancer metastasis. Cell Cycle. 2009; 8(20):3267-73. PMC: 3702728. DOI: 10.4161/cc.8.20.9699. View

Tanaka M, Hashiguchi Y, Ueno H, Hase K, Mochizuki H . Tumor budding at the invasive margin can predict patients at high risk of recurrence after curative surgery for stage II, T3 colon cancer. Dis Colon Rectum. 2003; 46(8):1054-9. DOI: 10.1007/s10350-004-7280-z. View

Krantz S, Shields M, Dangi-Garimella S, Munshi H, Bentrem D . Contribution of epithelial-to-mesenchymal transition and cancer stem cells to pancreatic cancer progression. J Surg Res. 2011; 173(1):105-12. PMC: 3278560. DOI: 10.1016/j.jss.2011.09.020. View

Guarino M, Rubino B, Ballabio G . The role of epithelial-mesenchymal transition in cancer pathology. Pathology. 2007; 39(3):305-18. DOI: 10.1080/00313020701329914. View

Friedl P, Gilmour D . Collective cell migration in morphogenesis, regeneration and cancer. Nat Rev Mol Cell Biol. 2009; 10(7):445-57. DOI: 10.1038/nrm2720. View

Thiery J, Sleeman J . Complex networks orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell Biol. 2006; 7(2):131-42. DOI: 10.1038/nrm1835. View

Floor S, van Staveren W, Larsimont D, Dumont J, Maenhaut C . Cancer cells in epithelial-to-mesenchymal transition and tumor-propagating-cancer stem cells: distinct, overlapping or same populations. Oncogene. 2011; 30(46):4609-21. DOI: 10.1038/onc.2011.184. View

Kajita M, McClinic K, Wade P . Aberrant expression of the transcription factors snail and slug alters the response to genotoxic stress. Mol Cell Biol. 2004; 24(17):7559-66. PMC: 506998. DOI: 10.1128/MCB.24.17.7559-7566.2004. View

10.

Alexander S, Koehl G, Hirschberg M, Geissler E, Friedl P . Dynamic imaging of cancer growth and invasion: a modified skin-fold chamber model. Histochem Cell Biol. 2008; 130(6):1147-54. DOI: 10.1007/s00418-008-0529-1. View

11.

Visvader J, Lindeman G . Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer. 2008; 8(10):755-68. DOI: 10.1038/nrc2499. View

12.

Sell S . Potential gene therapy strategies for cancer stem cells. Curr Gene Ther. 2006; 6(5):579-91. DOI: 10.2174/156652306778520674. View

13.

Lehn S, Tobin N, Berglund P, Nilsson K, Sims A, Jirstrom K . Down-regulation of the oncogene cyclin D1 increases migratory capacity in breast cancer and is linked to unfavorable prognostic features. Am J Pathol. 2010; 177(6):2886-97. PMC: 2993304. DOI: 10.2353/ajpath.2010.100303. View

14.

Masugi Y, Yamazaki K, Hibi T, Aiura K, Kitagawa Y, Sakamoto M . Solitary cell infiltration is a novel indicator of poor prognosis and epithelial-mesenchymal transition in pancreatic cancer. Hum Pathol. 2010; 41(8):1061-8. DOI: 10.1016/j.humpath.2010.01.016. View

15.

Yeung T, Gandhi S, Wilding J, Muschel R, Bodmer W . Cancer stem cells from colorectal cancer-derived cell lines. Proc Natl Acad Sci U S A. 2010; 107(8):3722-7. PMC: 2840416. DOI: 10.1073/pnas.0915135107. View

16.

Schmalhofer O, Brabletz S, Brabletz T . E-cadherin, beta-catenin, and ZEB1 in malignant progression of cancer. Cancer Metastasis Rev. 2009; 28(1-2):151-66. DOI: 10.1007/s10555-008-9179-y. View

17.

Jung A, Schrauder M, Oswald U, Knoll C, Sellberg P, Palmqvist R . The invasion front of human colorectal adenocarcinomas shows co-localization of nuclear beta-catenin, cyclin D1, and p16INK4A and is a region of low proliferation. Am J Pathol. 2001; 159(5):1613-7. PMC: 1867079. DOI: 10.1016/s0002-9440(10)63007-6. View

18.

Mani S, Guo W, Liao M, Eaton E, Ayyanan A, Zhou A . The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 2008; 133(4):704-15. PMC: 2728032. DOI: 10.1016/j.cell.2008.03.027. View

19.

Katoh M . Network of WNT and other regulatory signaling cascades in pluripotent stem cells and cancer stem cells. Curr Pharm Biotechnol. 2010; 12(2):160-70. DOI: 10.2174/138920111794295710. View

20.

Li Y, Kong D, Ahmad A, Bao B, Sarkar F . Pancreatic cancer stem cells: emerging target for designing novel therapy. Cancer Lett. 2012; 338(1):94-100. PMC: 3399061. DOI: 10.1016/j.canlet.2012.03.018. View